Hopp til innhold

Bergen Teknologioverføring (BTO) har skiftet navn til VIS.

Du har nå kommet til VIS sin nye nettside. Visinnovasjon.no erstatter nettsidene bergento.no og nyskapingsparken.no.

Det formelle navneskiftet ble foretatt 14. februar 2019.

Visinnovasjon.no > Aktuelt > BerGenBio AS raised NOK 52 MILL funding from investor group
VIS logo Logo for VIS

BerGenBio AS raised NOK 52 MILL funding from investor group

The biotech company BerGenBio AS has now raised NOK 52 MILL funding from an investor group to finance a large clinical study with purpose to develop new cancer medicine.
09.01.2012

The BTO fund Norsk Innovasjonskapital II is one of the partners in this investor group, as well as the Bergen billionaire Trond Mohn. BTO has also contributed in the development and implementation of strategy, some legal aspects and accounting. BerGenBio is a spin-out company from BTO, and has experienced rapid growth the last year now counting 14 employees.

The national newspaper Dagens Næringsliv has today published this news, read the complete article here (no longer available)

ekspander_ikon_20x20_svartekspander_ikon_20x20fb_28x28footer_vislogo_167x85hopptil-pilinsta_28x28kvitpil_ikon_19x13linkedin_28x28logo_toppmeny_vis_logo_59x50nfr_merke_250x103nonameraudpil_ikon_19x13siva-partner_hoover_291x48siva-partner_liggende_291x48twitter_28x28